TY - JOUR
T1 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision
AU - Bandelow, Borwin
AU - Zohar, Joseph
AU - Hollander, Eric
AU - Kasper, Siegfried
AU - Möller, Hans Jurgen
AU - Allgulander, Christer
AU - Ayuso-Gutierrez, José
AU - Baldwin, David S.
AU - Bunevicius, Robertas
AU - Cassano, Giovanni
AU - Fineberg, Naomi
AU - Gabriels, Loes
AU - Hindmarch, Ian
AU - Kaiya, Hisanobu
AU - Klein, Donald F.
AU - Lader, Malcolm
AU - Lecrubier, Yves
AU - Lépine, Jean Pierre
AU - Liebowitz, Michael R.
AU - Lopez-Ibor, Juan José
AU - Marazziti, Donatella
AU - Miguel, Euripedes C.
AU - Oh, Kang Seob
AU - Preter, Maurice
AU - Rupprecht, Rainer
AU - Sato, Mitsumoto
AU - Starcevic, Vladan
AU - Stein, Dan J.
AU - van Ameringen, Michael
AU - Vega, Johann
PY - 2008
Y1 - 2008
N2 - In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
AB - In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
KW - Anticonvulsants
KW - Antidepressants
KW - Antipsychotics
KW - Anxiety disorders
KW - Anxiolytics
KW - Benzodiazepines
KW - Cognitive behaviour therapy
KW - Evidence-based guidelines
KW - Generalized anxiety disorder
KW - Obsessive-compulsive disorder
KW - Panic disorder
KW - Post-traumatic stress disorder
KW - SNRI
KW - SSRI
KW - Simple phobia
KW - Social phobia
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=54949154218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54949154218&partnerID=8YFLogxK
U2 - 10.1080/15622970802465807
DO - 10.1080/15622970802465807
M3 - Article
C2 - 18949648
AN - SCOPUS:54949154218
SN - 1562-2975
VL - 9
SP - 248
EP - 312
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 4
ER -
